InvestSMART

4DMedical Limited (ASX:4DX)

ALERT: Price-sensitive ASX Announcement for 4DX
Current share price for 4DX : $4.100 -0.19 (-4.43%)+
Announcement
Release
15 Jan 2026 9:56AM
Price at Release
$4.290
Full Release
download
Summary
4DMedical Limited announced the completion of a $150 million institutional placement to accelerate the commercialization of its CT:VQ™ product in the U.S. market. The placement, priced at $3.80 per share, was supported by global institutional investors and resulted in minimal dilution for existing shareholders. The funds will primarily be used for research, development, and marketing efforts to drive adoption across academic medical centers in the U.S. CEO Andreas Fouras and CFO Julian Sutton increased their shareholdings through option exercises. CT:VQ™ has seen significant adoption in major U.S. medical centers post-FDA clearance.
Key Points
  • 4DMedical Limited completed a $150 million institutional placement at an issue price of $3.80 per share.
  • The placement was supported by both new and existing global institutional investors.
  • The funds will be used to accelerate the U.S. commercialisation of CT:VQ™ and for research and development, sales, marketing, customer support, and general administration.
  • The placement resulted in a 3.86% dilution to existing shareholders.
  • CT:VQ™ has been rapidly adopted by leading U.S. academic medical centers following FDA clearance.
  • CEO Andreas Fouras and CFO Julian Sutton exercised options to increase their shareholdings in the company.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.